Patents by Inventor Roger J. Davis
Roger J. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210023118Abstract: Methods for treating cancer, and for reducing angiogenesis in a tissue, comprising administering one or more of a miR-371 oligonucleotide; a miR-146 oligonucleotide; or an inhibitor of MLK2/3 activity.Type: ApplicationFiled: April 5, 2019Publication date: January 28, 2021Inventors: Shashi Kant, Siobhan Craige, John F. Keaney, JR., Roger J. Davis
-
Publication number: 20190381125Abstract: The disclosure provides methods and compositions for treating angiogenesis-related disorders, e.g., peripheral arterial disease (PAD), tissue ischemia, etc., using an agent that inhibits C-Jun N-terminal kinase 3 (JNK3) expression and/or activity. Specifically, the disclosure provides methods of treating angiogenesis-related disorders in a subject, the methods comprising administering to the subject a therapeutically effective amount of an agent that inhibits JNK3 expression and/or activity, wherein the agent is an inhibitory nucleic acid, a peptide, or peptide-inhibitor.Type: ApplicationFiled: February 14, 2018Publication date: December 19, 2019Inventors: Roger J. Davis, John F. Keaney, JR., Kasmir Ramo
-
Publication number: 20150313881Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: April 29, 2015Publication date: November 5, 2015Inventors: ROGER J. DAVIS, ANJA JAESCHKE
-
Patent number: 9061009Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.Type: GrantFiled: June 9, 2008Date of Patent: June 23, 2015Assignee: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20140107123Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: August 5, 2013Publication date: April 17, 2014Applicant: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 8501812Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: March 1, 2011Date of Patent: August 6, 2013Assignee: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20120240247Abstract: The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders, Alzheimer's disease, Huntington disease, Parkinson's disease, and ischaemia.Type: ApplicationFiled: December 16, 2011Publication date: September 20, 2012Inventors: Roger J. Davis, Richard A. Flavell, Pasko Rakic, Alan J. Whitmarsh, Chia-Yi Kuan, Derek Di Yang
-
Publication number: 20120208846Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: March 1, 2011Publication date: August 16, 2012Inventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 7897572Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: December 21, 2006Date of Patent: March 1, 2011Assignee: University Of Massachusetts Medical SchoolInventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 7838294Abstract: JNK-interacting protein 1 (JIP-1), an inhibitor of the JNK1 protein, and methods of treating a pathological condition or of preventing the occurrence of a pathological condition in a patient by the administration of a therapeutically effective amount of JIP-1 polypeptides, peptides, peptide mimetics, or nucleic acids are described.Type: GrantFiled: June 23, 2006Date of Patent: November 23, 2010Assignee: University of MassachusettsInventors: Roger J. Davis, Martin Dickens
-
Publication number: 20100215665Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.Type: ApplicationFiled: June 9, 2008Publication date: August 26, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20100183633Abstract: Biomarkers for JNK inhibition are described that can be used for monitoring effectiveness of JNK inhibitors and monitoring treatment with JNK inhibitors.Type: ApplicationFiled: December 4, 2009Publication date: July 22, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Roger J. DAVIS, Guadalupe SABIO BUZO, Madhumita DAS
-
Publication number: 20090053231Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.Type: ApplicationFiled: June 18, 2008Publication date: February 26, 2009Inventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
-
Patent number: 6943000Abstract: The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders, Alzheimer's disease, Huntington disease, Parkinson's disease, and ischaemia.Type: GrantFiled: October 2, 1998Date of Patent: September 13, 2005Assignees: University of Massachusetts, Yale UniversityInventors: Roger J. Davis, Richard A. Flavell, Pasko Rakic, Alan J. Whitmarsh, Chia-Yi Kuan, Derek Di Yang
-
Patent number: 6610523Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.Type: GrantFiled: June 13, 2000Date of Patent: August 26, 2003Assignee: University of MassachusettsInventors: Roger J. Davis, Alan Whitmarsh, Cathy Tournier
-
Publication number: 20030129606Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.Type: ApplicationFiled: May 3, 2002Publication date: July 10, 2003Applicant: University of Massachusetts, a Massachusetts corporationInventors: Roger J. Davis, Alan Whitmarsh, Cathy Tournier
-
Patent number: 6541605Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.Type: GrantFiled: April 7, 1998Date of Patent: April 1, 2003Assignee: University of MassachusettsInventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard
-
Publication number: 20030023990Abstract: The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders, Alzheimer's disease, Huntington disease, Parkinson's disease, and ischaemia.Type: ApplicationFiled: October 2, 1998Publication date: January 30, 2003Applicant: University of MassachusettsInventors: ROGER J. DAVIS, RICHARD A. FLAVELL, PASKO RAKIC, ALAN J. WHITMARSH, CHIA-YI KUAN, DEREK DI YANG
-
Publication number: 20020119135Abstract: JNK-interacting protein 1 (JIP-1), an inhibitor of the JNK1 protein, and methods of treating a pathological condition or of preventing the occurrence of a pathological condition in a patient by the administration of a therapeutically effective amount of JIP-1 polypeptides, peptides, peptide mimetics, or nucleic acids are described.Type: ApplicationFiled: April 2, 2002Publication date: August 29, 2002Inventors: Roger J. Davis, Martin Dickens
-
Publication number: 20020102691Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.Type: ApplicationFiled: January 16, 2001Publication date: August 1, 2002Applicant: University of Massachusetts, a Massachusetts corporationInventors: Roger J. Davis, Joel Raingeaud, Benoit Derijard